Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with RET -altered solid tumors in the US.
Naleen Raj BhandariAdrienne M GilliganJulie MyersAmine Ale-AliLee SmolenPublished in: Journal of medical economics (2024)
Three-year incremental PMPM cost estimates suggest a modest impact on payer-budgets associated with introduction of tumor-agnostic selpercatinib treatment.
Keyphrases